The American Academy of Dermatology (AAD) was founded in 1938 and is the largest and most influential dermatologic association. The association holds its 2023 annual meeting on March 17-21 with over 8,000 medical personnel and over 350 international exhibiting companies in the city of Jazz, New Orleans, Louisiana, USA. 

The results of a recent study in Rosacea, which was carried out in collaboration between SCARLETRED, GALDERMA and the University of Tübingen, will be presented at this year's AAD Annual Summit. The study “Ivermectin Treatment in Rosacea: How Novel Smartphone Technology Can Support Monitoring Rosacea-Associated Signs and Symptoms” (2022) successfully implemented and made use of the skin image documentation and analysis platform Scarletred®Vision by combining a clinical report outcome questionnaires with the medical device certified measurement functions of the system. The imaging system objectively documented visual changes in the skin texture and erythema over treatment time. By using its medical device certified measurement functions, the study team was able to confirm that treatment with ivermectin 1% cream is efficient in treating not only Rosacea-associated papules and pustules, but also changes in skin erythema (Standardized Erythema Value = SEV) and skin texture .

The obtained results were in alignment with clinically recorded visible as well as invisible symptoms of the disease, making SOOLANTRA® (ivermectin) Cream 1%, the first Rosacea product on the market whose therapeutic effect could be confirmed by the certified medical device software system, Scarletred®Vision.

In order to obtain more information about the possible use scope of Scarletred® technology in Rosacea or in a related disease, or if you want to meet in person with one of our experts at the AAD in New Orleans, please reach out to office@scarletred.com. We are happy to get in contact with you!

For more information about the event please visit the AAD homepage.